

SENATE HEALTH COMMITTEE

STATEMENT TO

SENATE RESOLUTION No. 20

STATE OF NEW JERSEY

DATED: MARCH 14, 1996

The Senate Health Committee reports favorably Senate Resolution No. 20.

This Senate resolution memorializes the Congress of the United States to address the issue of delays in approvals and increased costs associated with the current process of reviewing new drugs, biological products and medical devices by the United States Food and Drug Administration, by enacting comprehensive legislation to facilitate the rapid review and approval of innovative new drugs, biological products, and medical devices, without compromising patient safety or product effectiveness.